Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revive Therapeutics Ltd (OP: RVVTF ) 0.0068 UNCHANGED Streaming Delayed Price Updated: 3:57 PM EST, Nov 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Revive Therapeutics Ltd < Previous 1 2 3 4 5 6 7 8 9 Next > EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves July 31, 2024 Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. Via Benzinga Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More April 05, 2023 Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... Via Benzinga MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update April 03, 2023 Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to... Via Benzinga Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment March 28, 2023 Life sciences company Revive Therapeutics Ltd. Via Benzinga Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More February 13, 2023 Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Via Benzinga MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations February 06, 2023 Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve Via Benzinga PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch February 03, 2023 Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. Via Benzinga Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More January 17, 2023 Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. Via Benzinga Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders January 12, 2023 Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< Via Benzinga Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More December 19, 2022 Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Via Benzinga Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials December 16, 2022 Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). Via Benzinga Revive Therapeutics To Raise Up To $5M Via Private Placement December 01, 2022 REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. Via Benzinga Psychedelic Stock Gainers And Losers From November 30, 2022 November 30, 2022 Via Benzinga Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today November 29, 2022 Via Benzinga Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today November 28, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 25, 2022 November 25, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 24, 2022 November 24, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 23, 2022 November 23, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 22, 2022 November 22, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 21, 2022 November 21, 2022 Via Benzinga Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today November 18, 2022 Via Benzinga Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today November 17, 2022 Via Benzinga Psychedelic Stock Gainers And Losers From November 16, 2022 November 16, 2022 Via Benzinga GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today November 15, 2022 Via Benzinga Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today November 10, 2022 GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 Via Benzinga Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today November 09, 2022 GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: Via Benzinga Psychedelic Stock Gainers And Losers From November 8, 2022 November 08, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 Via Benzinga Compass Pathways, Allied Among Top Psychedelic Movers Of Today November 07, 2022 GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 Via Benzinga Psychedelic Stock Gainers And Losers From November 3, 2022 November 03, 2022 GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 Via Benzinga Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today November 02, 2022 GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
